Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System

Bernard Bonnotte, Nicolas Larmonier, Nathalie Favre, Annie Fromentin, Monique Moutet, Monique Martin, Sandeep Gurbuxani, Eric Solary, Bruno Chauffert, and François Martin

Immunization can prevent tumor growth, but the effector cells directly responsible for tumor cell killing in immunized hosts remain undetermined. The present study compares tumor grafts that progress in naive syngeneic rats with the same grafts that completely regress in hosts preimmunized with an immunogenic cell variant. The progressive tumors contain only a few macrophages that remain at the periphery of the tumor without direct contact with the cancer cells. These macrophages do not kill tumor cells in vitro. In contrast, tumors grafted in immunized hosts and examined at the beginning of tumor regression show a dramatic infiltration with mature macrophages, many of them in direct contact with the cancer cells. These macrophages are strongly cytotoxic for the tumor cells in vitro. In contrast to macrophages, tumor-associated lymphocytes are not directly cytotoxic to the tumor cells, even when obtained from tumor-immune rats. However, CD4\(^+\) and CD8\(^+\) T cells prepared from the regressing tumors induce tumoricidal activity in splenic macrophages from normal or tumor-bearing rats and in macrophages that infiltrate progressive tumors. These results strongly suggest that the main tumoricidal effector cells in preimmunized rats are macrophages that have been activated by adjacent tumor-immune lymphocytes. The Journal of Immunology, 2001, 167: 5077–5083.

The ability of specific T cells from tumor-immune animals to induce tumor regression is well-established in several experimental models of adoptive immunotherapy using T cell transfer. However, the ultimate mechanism(s) responsible for tumor cell killing are still unclear. It is often advanced that, in tumor-immune hosts, neoplastic cells are directly destroyed by CD8\(^+\) T cells activated as CTL. However, this possibility was not substantiated by immunohistological data and analysis of tumoricidal properties of tumor-infiltrating lymphocytes (TIL) upon recovery from regressive tumors in the immunized hosts (reviewed in Ref. 1). Tumoricidal activity of TIL is usually low, even after in vitro restimulation, and requires relatively large E:T ratios (2). Furthermore, cytolytic activity of T cells, which requires direct contact with the tumor target cells, is limited by migration of activated CD8\(^+\) T cells away from the tumor site (3). Recent studies have shown that tumoricidal activity after adoptive transfer of CD8\(^+\) T cells was independent of both perforin and Fas ligand pathways, suggesting that this effect was not related to a direct cytotoxic effect on the tumor cells (1). Thus, the prevailing role of CTL in tumor cell destruction remains questionable.

The experimental progressive/regressive (PRO/REG)\(^3\) tumor cell system (4) is a well-suited rat model to determine the precise nature of the cells involved in tumor cell destruction in immunized hosts. PRO and REG tumor cell clones were established from a chemically induced colon carcinoma growing in a strain of inbred rats (4). These clones constitutively differ in immunogenicity and tumorigenicity in syngeneic hosts (4, 5). The PRO clones give rise to progressive, metastatic, and lethal tumors. The REG clones, which yield spontaneously regressive tumors, induce a strong tumor-specific immune response that fully and durably protects the rats against subsequent PRO cell or parental tumor injection (6). The spontaneous regression of the REG tumors is related to a T cell-dependent immune response because REG cells give rise to progressive tumors in the nude mice or cyclosporine-treated syngeneic rats (7). Induction of an efficient anti-tumor immune response by REG cells is now well documented (8, 9). We have demonstrated that tumor Ags liberated by early death of a part of these tumor cells following s.c. injection are endocytosed by phagocytic cells which differentiate into dendritic cells. These cells migrate to the draining lymph nodes where they are able to present these Ags and to stimulate specific anti-tumor T cells. However, REG tumor regression is not associated with the appearance of cytotoxic T cells or the increase in NK cell activity in the spleen and in tumor-associated lymphocytes (10).

A study designed to determine the precise nature of effector cells responsible for ultimate elimination of the REG tumors is limited by the small size of these tumors before complete regression. Furthermore, even though a tumor-specific immune response is the predominant mechanism of REG tumor rejection (7), other factors such as spontaneous death of REG cells (8) may contribute to it. To circumvent this problem, we grafted established PRO tumors in rats that have been previously immunized with REG cells. These tumors continue their progression in naive rats but are invariably rejected in immunized rats. In this rat model system, immunohistochemical analyses with complementary in vitro functional studies led us to identify macrophages as the direct effectors of tumor cell killing. Furthermore, tumor-associated lymphocytes that are unable to destroy tumor cells independently are instrumental for macrophage activation.
Materials and Methods

Materials

Recombinant rat IFN-γ, anti-rat IFN-γ, anti-rat TNF-α Abs, and a colorimetric ELISA kit for rat IFN-γ (QuantiKine) were obtained from R&D Systems (Oxon, U.K.). LPS from Escherichia coli, serotype 0128:B12, and N⁴-methyl-L-arginine (NMMA) were obtained from Sigma (St. Louis, MO).

Animals, cell lines, and tumorigenicity assays

Animals used in these experiments were BD-IX strain rats bred in our laboratory by brother-sister mating. Animal use and handling were approved by the local Veterinary Committee and were performed according to the French laws for animal experimentation. Two cell lines, the regressive variant DHD-K12/TSb (REGb) and the progressive variant DHD-K12/TRb (PROb) were established from the tumor DHD, a colon adenocarcinoma induced by 1–2 dimethyldihydrazine in a BD-IX strain female rat (4). GV1A cell line was established from a glioma induced by N-ethyl-N-nitrosourea in a BD-IX rat (11). These tumor cells were cultured in Ham’s F10 medium (BioWhittaker, Verviers, Belgium) complemented with 10% FBS (Life Technologies, Paisley, Scotland), as previously described (5). For the tumorigenicity assays, 10⁶ PROb tumor cells in 100 μl of serum-free Ham’s F10 medium were injected s.c. into the anterolateral thoracic wall of syngeneic BD-IX rats. Four weeks later, the resulting PRO tumor was resected, and tumor pieces weighing ~50 mg were immediately grafted s.c. into the thoracic wall, at distance from the site of REGb cell-immunizing injections. Tumor volume was evaluated weekly, using a caliper to measure two perpendicular diameters.

Histological study of the tumor cell injection site

Immunized and naive rats were sacrificed 7, 14, or 21 days after the tumor graft. The tumor was resected, embedded in Tissue-Tek (Miles, Elkhart, IN), and snap-frozen in methylbutane cooled in liquid nitrogen. An immunohistochemical study of tumor-infiltrating inflammatory cells was performed on acetone-fixed 5 μM cryostat sections. Murine mAbs to rat leukocyte markers, obtained from Serotec (Oxford, U.K.), were used on serially cut sections. Tumor cells were also labeled with a specific mAb (12C) raised against PROb cells. After incubation with specific mAbs, sections were incubated with biotinylated sheep Ab to mouse IgG (Amer sham, Arlington Heights, IL), then with streptavidin-peroxidase and stained with aminoethylcarbazole.

Cytotoxicity studies

Rats were immunized with three s.c. injections of 10⁶ REGb cells, 1 mo apart. Macrophages were prepared from spleens of one or two naive or immunized rats, with or without 14-day-old PROb tumor grafts. Tumor grafts were performed 2 wk after the last immunizing injection. A spleen cell suspension was prepared by pressing the spleen through a stainless-steel wire mesh into RPMI 1640 culture medium (Life Technologies, Cergy-Pontoise, France) supplemented with 10% FBS. Tumor-infiltrating cells were purified from tumor grafts resected from groups of five to eight rats, pooled, cut in small fragments, and dissociated with 0.5 mg/ml collagenase (type II; Sigma) and 0.05 mg/ml DNase (type II; Sigma) for 1 h at 37°C in 5% CO₂ in poly(2-hydroxyethyl methacrylate)-coated vessels (Sigma) to prevent macrophage attachment. The subsequent steps for purifying tumor-infiltrating cells were performed at 4°C. Tumor cells were depleted by incubating cell suspensions with tumor cell-specific mAb 12C, then harvesting the mAb-labeled cells on anti-mouse IgG-coated magnetic beads (Dynabeads M450; Dynal Biotech, Oslo, Norway). Macrophage concentrations in spleen and tumor cell suspensions were estimated by counting cell numbers on a hemocytometer glass surface at 37°C in 5% CO₂. One to 2 × 10⁶ macrophages could be recovered from each individual tumor. For preparing macrophage culture, tumor-infiltrating cells containing 1 × 10⁵ macrophages/ml were incubated in flat-bottom 96-well plates (Nunclon, Roskilde, Denmark). After 2 h of incubation at 37°C in 5% CO₂, nonadherent cells were harvested and the plates were washed twice with PBS to remove all the nonadherent cells. Cells (~95%) adherent cells were shown to be macrophages according to their morphology and labeling with mAb ED2. Most harvested nonadherent cells were lymphocytes. In some experiments, CD4⁺ and CD8⁻ T cells were positively selected, following manufacturer’s instructions, using magnetic cell sorting after marking the nonadherent cell suspension with MicroBeads (Miltenyi Biotec, Paris, France) conjugated with mouse mAb anti-rat CD4 and CD8α-chain, respectively. The enrichment in CD4⁺ and CD8⁻ cells was 90 and 98%, respectively, when assayed on rat spleen cells in preliminary experiments. Macrophages with or without lymphocytes were cocultured in triplicate with tumor cells (1 × 10⁵ cells/ml) in RPMI 1640 medium supplemented with 10% FBS for 48 h at 37°C in a 5% CO₂ atmosphere. The lymphocyte/macrophage/tumor cell ratio was 30:10:1 in these experiments. At the end of this incubation period, culture medium was harvested, centrifuged, and immediately frozen at ~−20°C until cytokine assays were performed. The wells were gently washed twice with PBS, then the cultures were fixed for 15 min with methanol. The plates were allowed to dry, and labeled for 30 min at room temperature with 1% crystal violet, a protein-labeling dye that stains tumor cells that remain attached to the wells after the incubation period. The plates were carefully washed under tap water and dried, and the dye staining the residual tumor cells was eluted in 100 μl of 33% acetic acid in water (v/v). The absorbance of the eluted dye in each well was read at 570 nm on a Labtec scan (Bio-Advance, Emerainville, France). Triplicate wells were used to determine mean and SD. We checked that absorbance correlated linearly with the number of remaining viable tumor cells. Cell survival was determined by comparing cell viability in PROb cells in mixed culture with that of PROb cells alone. Macrophages did not contribute to the absorbance as they poorly fixed crystal violet.

Results

Regression of tumor grafts in immunized animals

PRO tumor pieces weighing ~50 mg were invariably accepted when engrafted in naive syngeneic hosts and continued to grow as progressive tumors. In contrast, rats immunized by three monthly s.c. injections of 1 × 10⁶ REGb cells systematically rejected PROb tumors gifted 2 wk after the last REGb cell injection. In these rats, tumors began to shrink from day 12 until complete disappearance 4–8 wk later (Fig. 1).

Regressioning PROb tumors were massively infiltrated by macrophages

To analyze the regression mechanisms, immunohistological analyses were performed on regressing tumors in the immunized animals as well as progressive tumors in the naive rats on days 7, 14, and 21 postgrafting. The most significant differences were observed on day 14, at the beginning of tumor regression in immunized rats. At this time, tumor cells were easily identifiable according to their typical morphology, 12C positivity (Fig. 2A), and the formation of poorly differentiated dense nodules. Progressive tumors in naive rats showed a peripheral halo of different inflammatory cells including ED1⁺ monocytes and immature dendritic

![FIGURE 1. Growth of the tumor grafts in naive and immune rats. PROb tumor pieces (~50-mg weight) were s.c. grafted in naive animals (○) and animals immunized by three injections of REGb cells, 1 mo apart. 2 wk before the PROb tumor graft (●). The curves represent the mean ± SD of two independent experiments on a total of 10 rats in each group. All the tumors that were grafted in naive rats progressed, and rats were sacrificed at the 4th wk. All the tumors that were grafted in immunized rats completely disappeared by the 8th wk.](image-url)
cells (Fig. 2B), and few, if any, ED2\(^{+}\)-stained mature macrophages (Fig. 2C). TCR\(^{+}\) T cells were also restricted to the tumor periphery (Fig. 2D) and were either CD4\(^{+}\) (Fig. 2E) or CD8\(^{+}\) (Fig. 2F). A few cells, also limited to the tumor periphery, expressed MHC class II molecules (Fig. 2G). In contrast, regressing tumors in immunized rats showed a spectacular infiltration by ED2\(^{+}\) mature macrophages within the tumor nodule (Fig. 2C). ED1\(^{+}\)-staining cells (Fig. 2B), as well as TCR\(^{+}\), CD4\(^{+}\), and CD8\(^{+}\) T cells (Fig. 2, D–F), which were more abundant in these regressive tumor nodules, remained at the periphery of the tumor. TCR\(^{+}\) CD8\(^{+}\) cells infiltrating the tumor nodules (Fig. 2, D and F) were observed to be large, irregular cells with a cytoplasmic staining. These cells are likely to be macrophages as they correspond in morphology and location to ED2\(^{+}\) tumor-infiltrating macrophages, and rat macrophages were shown to express CD8 molecules (12). To determine whether the CD8\(^{+}\) cells found inside the tumor nodules were CD8\(^{+}\) lymphoid cells (CTL or NK cells) or CD8\(^{+}\) macrophages, another mAb to rat CD8\(\alpha\), G28, was used. In contrast to OX8 mAb, which labels a rat CD8\(\alpha\) hinge region epitope expressed by both macrophages and lymphoid cells, G28 labels an Ig variable-like region epitope, which is expressed only by CTL and NK cells (13). Both OX8 and G28 Abs labeled cells at the periphery of the tumor nodules. Only OX8, but not G28, labeled CD8\(^{+}\) cells that infiltrated tumor nodules (Fig. 3). These CD8\(^{+}\)G28\(^{+}\) cells were also characterized by their elongated morphology and cytoplasmic staining, in contrast to the G28\(^{+}\) cells surrounding the tumor nodules that were characterized by a round shape and a predominantly cell surface labeling. Like TCR\(^{+}\) T cells, 3.2.3\(^{+}\) NK cells were more abundant in regressive than in progressive tumors but remained confined to the periphery of the tumor nodules (data not shown).

Macroaggregates but not lymphocytes that infiltrate regressive tumors dramatically kill tumor cells in vitro

Cytotoxicity assays were performed in vitro to determine the effects of tumor-infiltrating and splenic macrophages (adherent

![OX8](image1)

![G28](image2)

**FIGURE 3.** CD8 expression by cells infiltrating the regressive PROb tumor grafts. CD8\(^{+}\) cells were labeled using either an Ab (OX-8) that binds a CD8\(\alpha\) epitope expressed by both myeloid (macrophages) and lymphoid cells (CTL and NK cells), or an Ab (G28) that labels only CD8\(^{+}\) T cells and NK cells. Deep-frozen sections were stained with OX-8 or G28, a biotinylated anti-mouse IgG Ab, then avidin-FITC, were subsequently added. CD8\(^{+}\) cells surrounding the tumor nodules were labeled by both mAbs, whereas elongated CD8\(^{+}\) cells infiltrating the tumor nodules were predominantly labeled with OX-8 mAb, suggesting their myeloid origin (arrowheads).
cells) and lymphocytes (nonadherent cells) on PROb tumor cells. Tumor-infiltrating macrophages isolated 14 days after the graft in immune rats were strongly cytotoxic as they killed all tumor cells in a 48-h coculture assay at a 10:1 E:T ratio. In comparison, tumor-infiltrating macrophages isolated 14 days after the graft in nonimmune rats were also cytotoxic, but to a considerably lower extent, reducing tumor cell viability by only 32–45%. Splenic macrophages from naive and immune rats, either tumor-bearing or not, showed no significant cytotoxicity (Fig. 4A). Nonadherent cells, which were predominantly lymphocytes, were isolated from the spleen and tumor of naive or immunized rats. These cells showed no significant cytotoxicity to tumor cells even when used at a 30:1 E:T ratio (Fig. 4B). Similar results were obtained in five independent experiments. This macrophage-mediated cytotoxic effect was not restricted to cells from the colon cancer from which the PRO/REG cell variants originated. Macrophages from regressing PROb tumors also demonstrated cytotoxic activity toward a rat glioma cell line (Fig. 5A). We investigated also the mechanisms used by tumor-infiltrating macrophages for killing PROb cells. Addition of 1 mM NMMA, an inhibitor of NO generation from arginine, strongly inhibited PROb cell killing by macrophages from regressing PROb grafts, whereas macrophage-induced cytotoxicity was not influenced by an anti-TNF-α mAb (5 μg/ml) (Fig. 5B).

**Lymphocytes associated with regressive tumors in immune hosts induced macrophage activation**

When nonadherent cells infiltrating PROb tumors grafted in immune animals were added to splenic macrophages from normal, immune, or tumor-bearing rats, toxicity against tumor cells was dramatically increased and all the tumor cells were eliminated (Fig. 6A). Interestingly, when nonadherent cells infiltrating PROb tumors grafted in immune animals were added to macrophages
isolated from regressing tumor grafts because CD4+ or CD8+ T lymphocytes isolated from these nonadherent cells activated macrophages as efficiently as the whole nonadherent cell fraction, without any significant difference between CD4+ and CD8+ cells (Fig. 6B). Surprisingly, addition of both CD4+ and CD8+ cells had no more macrophage-activating activity than addition of CD4+ or CD8+ cells alone. This could indicate that each T cell subpopulation maximally activated splenic macrophages in this experiment. We did not determine whether immune T cells activated macrophages through a direct cell contact or through production of cytokines in the tumor microenvironment.

IFN-γ is a lymphokine known for its capacity for inducing rat macrophages to become cytotoxic against cancer cells. We found that lymphocytes isolated from PROb tumors grafted in immune rats secreted significant amounts of IFN-γ (455 ± 78 pg/ml) in the culture medium when cultured for 48 h with PROb cells and splenic macrophages.

**Tumoricidal activity of tumor-infiltrating and splenic macrophages from rats bearing progressive tumors can be induced by exposure to IFN-γ and bacterial LPS**

As neither splenic macrophages nor macrophages that infiltrated progressive tumors in nonimmunized rats were cytotoxic to tumor cells, we investigated whether tumoricidal activity could be induced by exogenous activators. Addition of IFN-γ and/or LPS strongly increased macrophage cytotoxicity to PROb cells (Fig. 7). IFN-γ alone did not induce a cytotoxicity sufficient to destroy all the tumor cells established in a monolayer, whereas LPS alone was almost as effective as LPS + IFN-γ for inducing macrophage-mediated cytotoxicity.

**Discussion**

Destruction of tumor cells in immunized hosts is generally attributed to a direct cytotoxic effect of CD8+ CTL (14–18). However, the lack of correlation between CTL induction and tumor rejection in immunotherapy trials calls into question the relevance of CD8+ T cell cytotoxicity as measurement of anti-tumor immune responses.
activity (19). In the present study using a rat model system we demonstrate that the effector cell directly responsible for tumor cell killing and tumor graft rejection in the immunized host is not a lymphoid cell, but an activated mature macrophage. Regressing tumor grafts in preimmunized hosts were heavily infiltrated by inflammatory cells that were labeled with ED2 mAb, a marker of mature rat macrophages (20). These tumor-infiltrating macrophages also express CD8 recognized by OX8 mAb but not G28 mAb, which specifically labels a CD8αβ epitope expressed only by lymphoid cells (13). These macrophages were in direct contact with tumor cells and strongly cytotoxic to them in vitro.

The capacity of activated macrophages to destroy tumor cells in vitro has been known for a long time (21–23). However, to the best of our knowledge, the role of macrophages in tumor rejection observed in specifically tumor-immunized hosts has never been analyzed. The mechanisms by which activated macrophages kill neoplastic cells include NO production through activation of inducible NO synthase, and TNF-α secretion (21–23). We demonstrate here that the cytotoxic effect of activated macrophages isolated from regressing tumors is suppressed by NMMA, an inhibitor of NO production, whereas this cytotoxic effect is not influenced by a blocking anti-TNF-α mAb, probably because PRO cells have no receptor to TNF-α (24). On paraffin-embedded sections, the damaged tumor cells were not stained after terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL), demonstrating that macrophage-induced tumor cell death does not imply DNA internucleosomal cleavage (result not shown).

Tumoricidal activity was restricted to macrophages infiltrating tumors engrafted in immunized hosts. Splenic macrophages from immunized rats were not cytotoxic. Macrophages infiltrating tumors in naive rats were few and sparse. Most of them were not in contact with the cancer cells and demonstrated only a limited cytotoxic effect toward tumor cells in vitro. These observations suggest that macrophages have to undergo in situ activation to exert tumoricidal function. Interestingly, tumor-asociated lymphocytes from immunized hosts induce the tumoricidal activity of inactive splenic macrophages from normal or tumor-bearing rats, as well as in macrophages isolated from PROb tumors grown in naive rats. This observation strongly suggests that lymphocytes that surround tumor nodules in immunized rats are stimulated in this local microenvironment, then deliver activation signals to macrophages that infiltrate these tumors.

In contrast with macrophages, T lymphocytes were located at the periphery of the regressing tumor nodules, were only infrequently observed to be in contact with the tumor cells, and had no direct cytotoxic effect against tumor cells, even at E:T ratios as high as 30:1. Passively transferred CD8+ T cells from tumor-immunized donors have been shown to induce complete, Th1 cytokine-dependent tumor regression in the recipient in the absence of any direct cytotoxic effect (1). Furthermore, the therapeutic effectiveness of tumor-infiltrating CD8+ T lymphocyte cultures correlates with their ability to secrete lymphokines rather than their cytotoxic capacity in vitro (25–27). CD8+ T cells, as well as CD4+ Th1 cells (28), are a source of cytokines such as IFN-γ, GM-CSF, and TNF-α, which can stimulate the tumoricidal activity of host cells, including tumor-associated macrophages. In agreement with these findings, IFN-γ levels measured in 48-h supernatants of macrophage, tumor cell, and TIL cocultures were higher for TIL isolated from immunized than from naive animals. Moreover, addition of IFN-γ, as well as endotoxin, to splenic or tumor-associated macrophages from naive animals generated significant cytotoxic activity in these otherwise noncytotoxic macrophages. In contrast to mouse macrophages that require two signals (a priming signal from IFN-γ and a progression signal from LPS) to become cytotoxic against cancer cells (29), a single exogenous stimulus, IFN-γ or LPS, activates rat resident macrophages for NO production and tumor cytotoxicity (30).

Progressive human tumors are frequently infiltrated by macrophages (31). However, these macrophages are not potent effectors of tumoricidal activity in the absence of stimulation and could even enhance tumor growth (reviewed in Ref. 32). Tumor cells could adversely alter macrophage tumoricidal activity (33). Interestingly, tumoricidal activity of macrophages isolated from progressive PROb tumors in naive animals could be restored in vitro by either exposure to lymphocytes isolated from the regressive tumors of immune rats, or exogenous stimuli such as IFN-γ and bacterial endotoxins. The effect of endotoxins is particularly interesting because peritoneal carcinomatosis that results from PROb cell i.p. injections into naive rats can be definitely cured upon multiple administrations of lipid A, an endotoxin component (34, 35).

We have previously demonstrated that tumor proteins released as a consequence of initial events following injection of REG cells in naive syngeneic rats are engulfed by inflammatory cells and transported to lymph node T cell areas (9). However, the protective immune response following REG tumor regression was not accompanied by a detectable increase in the specific or nonspecific cytotoxic activity of splenic and tumor-associated T lymphocytes and NK cells (10). In the present study, which was performed on the same rat tumor model, we clarified the downstream events and defined the effector cells involved in the final elimination of the tumors in immunized hosts. These events involve migration of activated tumor-specific T cells to the tumor site, local production of IFN-γ and possibly other cytokines that activate tumor-associated macrophages, and subsequent elimination of tumor cells by these macrophages. The present work also demonstrates that macrophages that infiltrate progressive tumors have the potential to destroy tumor cells, provided they receive appropriate T cell-mediated activation signals, such as cytokines, or nonimmune stimuli, such as bacterial endotoxins.

References

1. Winter, H., M. H. Hu, W. J. Urba, and B. A. Fox. 1999. Tumor regression after adoptive transfer of effector T-cells is independent of perforin or Fas ligand (APO-1/CD95L). J. Immunol. 163:8462.
2. Barth, R. J., Jr., J. J. Mule, P. J. Spiess, and S. A. Rosenberg. 1991. Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
3. Shirkan, P., and M. F. Mescher. 1999. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162:2858.
4. Martin, F., A. Cagnard, J. F. Jeannin, A. Leclerc, and M. S. Martin. 1983. Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int. J. Cancer 32:623.
5. Caignard, A., M. S. Martin, M. F. Michel, and F. Martin. 1985. Interaction between two cellular subpopulations of a rat colon carcinoma when inoculated to the syngeneic host. Int. J. Cancer 36:273.
6. Caignard, A., H. Pelletier, and F. Martin. 1988. Specificity of the immune response leading to protection or enhancement by progressive and regressive variants of a rat colon carcinoma. Int. J. Cancer 42:883.
7. Shimizu, T., M. S. Martin, H. Pelletier, P. Lagadec, and F. Martin. 1989. Effects of cyclosporine on progressive and regressive tumours induced by two cancer lines derived from a single colon carcinoma chemically induced in the rat. Immunobiology 178:401.
8. Bonnotte, B., N. Favre, M. Moutet, A. Fromentin, E. Solary, M. Martin, and F. Martin. 1998. Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J. Immunol. 161:1433.
9. Bonnotte, B., N. Favre, M. Moutet, A. Fromentin, E. Solary, M. Martin, and F. Martin. 2000. Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J. Immunol. 164:1995.
10. Pelletier, H., N. O. Olsson, G. Lizard, and F. Martin. 1991. Cytotoxic activity of lymphocytes infiltrating progressive and regressive tumors variants from a rat colon cancer. Immunobiology 182:188.
11. Cornain, S., C. Carnaud, D. Silverman, E. Klein, and M. F. Rajewsky. 1975. Spleen-cell reactivity against transplanted neurogenic rat tumors induced by ethyl nitrosourea: uncovering of tumor specificity after removal of complement-receptor bearing lymphocytes. *Int. J. Cancer* 16:301.

12. Hirji, N., T. J. Lin, and A. D. Befus. 1997. A novel CD8 molecule expressed by alveolar and peritoneal macrophages stimulates nitric oxide production. *J. Immunol.* 158:1833.

13. Lin, T. J., N. Hirji, G. R. Stenton, M. Gilchrist, B. J. Grill, A. D. Schreiber, and A. D. Befus. 2000. Activation of macrophage CD8: pharmacological studies of TNF and IL-1β production. *J. Immunol.* 164:1783.

14. Rosenau, W., and D. L. Morton. 1966. Tumor specific inhibition of growth of MCA induced sarcomas in vivo and in vitro by sensitized isologous lymphoid cells. *J. Natl. Cancer Inst.* 36:825.

15. Chauvenet, P. H., C. P. McArthur, and R. T. Smith. 1979. Demonstration in vitro of CTL with apparent specificity toward tumor specific transplantation antigens on chemically induced tumors. *J. Immunol.* 123:2375.

16. Fernandez-Cruz, E., B. Halliburton, and J. D. Feldman. 1979. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus induced sarcoma. *J. Immunol.* 123:1772.

17. Oehler, J. R., and R. B. Herberman. 1979. Evidence for long lasting tumor immunity in a syngeneic rat lymphoma model: correlation of in vivo findings with in vitro observations. *J. Natl. Cancer Inst.* 56:825.

18. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falco. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. *J. Exp. Med.* 183:283.

19. Pardoll, D. M. 1998. Cancer vaccines. *Clin. Exp. Metastasis* 15:35.

20. Dijkstra, C. D., E. A. Doorn, P. Joling, and G. Kraal. 1985. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. *Immunology* 54:589.

21. Evans, R., and P. Alexander. 1970. Cooperation of immune lymphoid cells with macrophages in tumor immunity. *Nature* 228:620.

22. Hibbs, J. B., L. H. Lambert, and J. S. Remington. 1972. Possible role of macrophage mediated non specific cytotoxicity in tumor resistance. *Nature* 235:48.

23. Piessev, W. F., W. H. Churchill, and J. R. David. 1975. Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. *J. Immunol.* 114:293.

24. Bonnotte, B., N. Favre, S. Reveneau, O. Micheau, N. Droin, C. Garrido, A. Fontana, B. Chaffert, E. Solary, and F. Martin. 1998. Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate. *Cell Death Differ.* 5:480.

25. Barth, R. J., Jr, J. J. Mule, P. J. Spiess, and S. A. Rosenberg. 1991. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. *J. Exp. Med.* 167:647.

26. Tuttle, T. M., C. W. McCrady, T. H. Inge, M. Salour, and H. D. Bear. 1993. γ-interferon plays a key role in T-cell-induced tumor regression. *Cancer Res.* 53:833.

27. Aruga, A., E. Aruga, M. J. Cameron, and A. E. Chang. 1997. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. *J. Leukocyte Biol.* 61:507.

28. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4+ T-cells in the antitumor immune response. *J. Exp. Med.* 188:2557.

29. Lorenbach, R. B., W. J. Murphy, C. J. Lowenstein, S. H. Snyder, and S. W. Russell. 1993. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor killing: molecular basis for the synergy between interferon-γ and lipopolysaccharide. *J. Biol. Chem.* 268:1908.

30. Lavnikova, N., J. C. Draper, and D. L. Laskin. 1993. A single exogenous stimulus activates resident rat macrophages for nitric oxide production and tumor cytotoxicity. *J. Leukocyte Biol.* 54:322.

31. Van Ravenswaay Claasen, H. H., P. M. Kluin, and G. J. Fleuren. 1992. Tumor infiltrating cells in human cancer: on the possible role of CD16+ macrophages in antitumor cytotoxicity. *Lab. Invest.* 67:166.

32. Mantovani, A., B. Bottazzi, F. Colotta, S. Sozzani, and L. Ruco. 1992. The origin and function of tumor-associated macrophages. *Immunol. Today* 13:265.

33. Elgert, K. D., D. G. Alleva, and D. W. Mullins. 1998. Tumor-induced immune dysfunction: the macrophage connection. *J. Leukocyte Biol.* 64:275.

34. Jeannin, J. F., N. Onier, P. Lagadec, N. Von Jeney, P. Stu, and E. Liehl. 1991. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. *Gastroenterology* 101:726.

35. Onier, N., S. Hilpert, L. Arnould, V. Saint-Giorgio, J. G. Davies, J. Bauer, and J. F. Jeannin. 1999. Cure of colon cancer metastasis in rats with the new lipid A OM174: apoptosis of tumor cells and immunization of rats. *Clin. Exp. Metastasis* 17:299.